ATON-JOURNEY |一文读懂ADC药物和DAR值分析（下篇）- 大数跨境

首页

ATON-JOURNEY |一文读懂ADC药物和DAR值分析（下篇）

安腾瑞霖

2024-11-08

导读：ATON-Journey 第26期

参考文献

Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022 Mar 22;7(1):93. doi: 10.1038 / s41392-022-00947-7.
Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2022 Jan;229:107917. doi: 10.1016 / j.pharmthera.2021.107917. Epub 2021 Jun 24.
Lucas AT, Price LSL, Schorzman AN, Storrie M, Piscitelli JA, Razo J, Zamboni WC. Factors Affecting the Pharmacology of Antibody-Drug Conjugates. Antibodies (Basel). 2018 Feb 7;7(1):10. doi: 10.3390 / antib7010010.
Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014 Jul;19(7):869-81. doi: 10.1016 / j.drudis.2013.11.004. Epub 2013 Nov 15.
Baah S, Laws M, Rahman KM. Antibody-Drug Conjugates-A Tutorial Review. Molecules. 2021 May 15;26(10):2943. doi: 10.3390/molecules26102943.
Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173-185. doi: 10.1248 / cpb.c18-00744.
Wagh A, Song H, Zeng M, Tao L, Das TK. Challenges and new frontiers in analytical characterization of antibody-drug conjugates. MAbs. 2018;10(2):222-243. doi: 10.1080 / 19420862.2017.1412025.
Matsuda Y, Mendelsohn BA. Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates. Chem Pharm Bull (Tokyo). 2021;69(10):976-983. doi: 10.1248 / cpb.c21-00258.
Chen Y. Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy. Methods Mol Biol. 2013; 1045:267-73. doi: 10.1007 / 978-1-62703-541-5_16.
Bobály B, Fleury-Souverain S, Beck A, Veuthey JL, Guillarme D, Fekete S. Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates. J Pharm Biomed Anal. 2018 Jan 5;147:493-505. doi: 10.1016/j.jpba.2017.06.022. Epub 2017 Jun 24.
Agilent Application Note 5994-2097EN.
Rodriguez-Aller M, Guillarme D, Beck A, Fekete S. Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatography, part 1: optimization of the mobile phase. J Pharm Biomed Anal. 2016 Jan 25;118:393-403. doi: 10.1016 / j.jpba.2015.11.011. Epub 2015 Nov 14.
Bobaly B, Beck A, Veuthey JL, Guillarme D, Fekete S. Impact of organic modifier and temperature on protein denaturation in hydrophobic interaction chromatography. J Pharm Biomed Anal. 2016 Nov 30;131:124-132. doi: 10.1016/j.jpba.2016.08.019. Epub 2016 Aug 26.
Cusumano A, Guillarme D, Beck A, Fekete S. Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatoraphy, part 2: Optimization of the phase system. J Pharm Biomed Anal. 2016 Mar 20;121:161-173. doi: 10.1016 / j.jpba.2016.01.037. Epub 2016 Jan 16.
Fleming R. ADC Analysis by Hydrophobic Interaction Chromatography. Methods Mol Biol. 2020;2078:147-161. doi: 10.1007 / 978-1-4939-9929-3_10.
Wagner-Rousset E, Colas O, François YN, Heinisch S, Guillarme D, Cianférani S, Beck A. Drug Loading and Distribution of ADCs After Reduction or IdeS Digestion and Reduction. Methods Mol Biol. 2020;2078:187-195. doi: 10.1007 / 978-1-4939-9929-3_12.
Waters Application Note. 720006368en.
Matsuda Y, Kliman M, Mendelsohn BA. Application of Native Ion Exchange Mass Spectrometry to Intact and Subunit Analysis of Site-Specific Antibody-Drug Conjugates Produced by AJICAP First Generation Technology. J Am Soc Mass Spectrom. 2020 Jul 1. doi: 10.1021/jasms.0c00129. Epub ahead of print.